Sudden cardiac death in congenital heart disease.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
06 06 2022
Historique:
received: 07 10 2021
revised: 22 02 2022
accepted: 03 01 2022
pubmed: 19 3 2022
medline: 9 6 2022
entrez: 18 3 2022
Statut: ppublish

Résumé

Sudden cardiac death (SCD) accounts for up to 25% of deaths in patients with congenital heart disease (CHD). To date, research has largely been driven by observational studies and real-world experience. Drawbacks include varying definitions, incomplete taxonomy that considers SCD as a unitary diagnosis as opposed to a terminal event with diverse causes, inconsistent outcome ascertainment, and limited data granularity. Notwithstanding these constraints, identified higher-risk substrates include tetralogy of Fallot, transposition of the great arteries, cyanotic heart disease, Ebstein anomaly, and Fontan circulation. Without autopsies, it is often impossible to distinguish SCD from non-cardiac sudden deaths. Asystole and pulseless electrical activity account for a high proportion of SCDs, particularly in patients with heart failure. High-quality cardiopulmonary resuscitation is essential to improve outcomes. Pulmonary hypertension and CHD complexity are associated with lower likelihood of successful resuscitation. Risk stratification for primary prevention implantable cardioverter-defibrillators (ICDs) should consider the probability of SCD due to a shockable rhythm, competing causes of mortality, complications of ICD therapy, and associated costs. Risk scores to better estimate probabilities of SCD and CHD-specific guidelines and consensus-based recommendations have been proposed. The subcutaneous ICD has emerged as an attractive alternative to transvenous systems in those with vascular access limitations, prior device infections, intra-cardiac shunts, or a Fontan circulation. Further improving SCD-related outcomes will require a multidimensional approach to research that addresses disease processes and triggers, taxonomy to better reflect underlying pathophysiology, high-risk features, early warning signs, access to high-quality cardiopulmonary resuscitation and specialized care, and preventive therapies tailored to underlying mechanisms.

Identifiants

pubmed: 35302168
pii: 6550411
doi: 10.1093/eurheartj/ehac104
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2103-2115

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Paul Khairy (P)

Montreal Heart Institute, Université de Montréal, 5000 Belanger St E., Montreal, QC, Canada H1T 1C8.

Michael J Silka (MJ)

Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Jeremy P Moore (JP)

Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA, USA.

James A DiNardo (JA)

Boston Children's Hospital, Harvard University, Boston, MA, USA.

Jim T Vehmeijer (JT)

Heart Center, Academic Medical Center-University of Amsterdam, Amsterdam, The Netherlands.

Mary N Sheppard (MN)

Cry Unit of Cardiovascular Pathology, St George's University of London, London, UK.

Alexander van de Bruaene (A)

Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.

Marie-A Chaix (MA)

Montreal Heart Institute, Université de Montréal, 5000 Belanger St E., Montreal, QC, Canada H1T 1C8.

Margarita Brida (M)

Department of Cardiovascular Medicine, University Hospital Centre, Zagreb, Croatia.

Benjamin M Moore (BM)

Royal Prince Alfred Hospital, University of Sydney, Camperdown, New South Wales, Australia.

Maully J Shah (MJ)

Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.

Blandine Mondésert (B)

Montreal Heart Institute, Université de Montréal, 5000 Belanger St E., Montreal, QC, Canada H1T 1C8.

Seshadri Balaji (S)

Division of Pediatric Cardiology, Oregon Health and Science University, Portland, OR, USA.

Michael A Gatzoulis (MA)

Royal Brompton & Harefield Hospitals, National Heart and Lung Institute, Imperial College, London, UK.

Magalie Ladouceur (M)

Hôpital Européen Georges Pompidou, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH